tiprankstipranks
Nuvectis Pharma reports FY22 EPS ($1.51), consensus ($1.41)
The Fly

Nuvectis Pharma reports FY22 EPS ($1.51), consensus ($1.41)

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented: "2022 was a very busy year for Nuvectis with significant progress made on both development programs. For NXP800, we continued to advance the Phase 1a dose escalation study in patients with various advanced solid tumors, and in December we announced that the Food and Drug Administration granted Fast Track Designation status to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma. Moreover, we recently announced that the European Network for Gynecological Oncology Trial groups and the GOG Foundation, Inc., the world’s premier gynecology oncology clinical trials consortia, will lead the upcoming Phase 1b clinical trial in ARID1a-mutated ovarian carcinoma, a disease comprised mostly of clear cell and endometrioid histologies. Lastly, the discovery and optimization work performed at the Institute of Cancer Research was showcased in the prestigious New Drugs on the Horizon session of the American Association for Cancer Research, and additional in-vivo preclinical data was generated that provides further potential development opportunities for NXP800."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on NVCT:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles